Cargando…

KDOAM-25 Overcomes Resistance to MEK Inhibitors by Targeting KDM5B in Uveal Melanoma

BACKGROUND: Uveal Melanoma (UM) is a potentially lethal cancer, and epigenetics may participate in the regulation of MEK resistance. This study is aimed at targeting the epigenetic kinase to overcome the resistance to MEK inhibitor. METHOD: We developed the 92.1 and OMM1 MEK-inhibitor resistant cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Hongjun, Liu, Xiangnan, Chen, Yong'an, Xu, Rui, He, Shengli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534647/ https://www.ncbi.nlm.nih.gov/pubmed/36212716 http://dx.doi.org/10.1155/2022/1556485

Ejemplares similares

Retracted: KDOAM-25 Overcomes Resistance to MEK Inhibitors by Targeting KDM5B in Uveal Melanoma
por: International, BioMed Research
Publicado: (2023)

Monosomy 3 Is Linked to Resistance to MEK Inhibitors in Uveal Melanoma
por: Mergener, Svenja, et al.
Publicado: (2021)

Histone deacetylase inhibitors: a promising partner for MEK inhibitors in uveal melanoma?
por: Faião-Flores, Fernanda, et al.
Publicado: (2019)

HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma
por: Sriramareddy, Sathya Neelature, et al.
Publicado: (2022)

Intermittent MEK inhibition for the treatment of metastatic uveal melanoma
por: Khan, Shaheer, et al.
Publicado: (2022)

FAK Inhibitor-Based Combinations with MEK or PKC Inhibitors Trigger Synergistic Antitumor Effects in Uveal Melanoma
por: Tarin, Malcy, et al.
Publicado: (2023)

Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study
por: Pópulo, Helena, et al.
Publicado: (2021)

Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines
por: von Euw, Erika, et al.
Publicado: (2012)

Impact of Combined mTOR and MEK Inhibition in Uveal Melanoma Is Driven by Tumor Genotype
por: Ho, Alan L., et al.
Publicado: (2012)

Uveal Melanoma
por: Papastefanou, Vasilios P., et al.
Publicado: (2011)

Uveal Melanoma
por: Pfeffer, Ulrich
Publicado: (2019)

A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma
por: Bauer, Sebastian, et al.
Publicado: (2023)

MEK inhibitors for the treatment of NRAS mutant melanoma
por: Sarkisian, Saro, et al.
Publicado: (2018)

Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma: Can We Thus Overcome Its High Resistance?
por: Blomen, Chiara L., et al.
Publicado: (2021)

MRI of Uveal Melanoma
por: Ferreira, Teresa A., et al.
Publicado: (2019)

The biology of uveal melanoma
por: Amaro, Adriana, et al.
Publicado: (2017)

Uveal Melanoma Metastasis
por: Rossi, Ernesto, et al.
Publicado: (2021)

Re-enforcing the strategy of targeting MEK/ERK signaling to overcome acquired resistance to third generation EGFR inhibitors
por: Zhao, Wen, et al.
Publicado: (2021)

A Predictive Model of Adaptive Resistance to BRAF/MEK Inhibitors in Melanoma
por: Ruiz, Emmanuelle M., et al.
Publicado: (2023)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

Trametinib: a MEK inhibitor for management of metastatic melanoma
por: Lugowska, Iwona, et al.
Publicado: (2015)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
por: Wang, Beike, et al.
Publicado: (2021)

Costunolide is a dual inhibitor of MEK1 and AKT1/2 that overcomes osimertinib resistance in lung cancer
por: Tian, Xueli, et al.
Publicado: (2022)

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
por: Corcoran, Ryan B., et al.
Publicado: (2011)

MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers
por: Wyce, Anastasia, et al.
Publicado: (2018)

DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
por: Izquierdo, Elisa, et al.
Publicado: (2022)

Gamma knife radiosurgery for the treatment of uveal melanoma and uveal metastases
por: Reynolds, Margaret M., et al.
Publicado: (2017)

Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK
por: Tran, Khanh B., et al.
Publicado: (2021)

Concurrent inhibition of FAK/SRC and MEK overcomes MEK inhibitor resistance in Neurofibromatosis Type I related malignant peripheral nerve sheath tumors
por: Gu, Yihui, et al.
Publicado: (2022)

Exoresection and Endoresection for Uveal Melanoma
por: Gündüz, Kaan, et al.
Publicado: (2010)

Uveal melanoma: Estimating prognosis
por: Kaliki, Swathi, et al.
Publicado: (2015)

YAP as oncotarget in uveal melanoma
por: Yu, Fa-Xing, et al.
Publicado: (2014)

DNA Methylation and Uveal Melanoma
por: Yang, Zhi-Kun, et al.
Publicado: (2018)

Role of Epigenetics in Uveal Melanoma
por: Li, Yongyun, et al.
Publicado: (2017)

Epidemiology of uveal melanoma in Brazil
por: Lucena, Evandro, et al.
Publicado: (2020)

Spliceosome Mutations in Uveal Melanoma
por: Nguyen, Josephine Q.N., et al.
Publicado: (2020)

Multicentric recurrent uveal melanoma
por: Menon, Vikas, et al.
Publicado: (2020)

Animal Models of Uveal Melanoma
por: Uner, Ogul E., et al.
Publicado: (2022)

Uveal Melanoma Metastasis to the Thyroid
por: Thanadar, Rokshana R., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fku0gqd557en7alpnelg02f6bt